Diligence memo · auto-generated · as of July 3, 2026
Nanospectra Biosciences Inc
Nanospectra Biosciences Inc looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Nanospectra Biosciences Inc operates in Biotech / Pharma, based in HOUSTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nanospectra Biosciences Inc has raised $22M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $8.6M on 2020-09-03.
Most recent recorded round closed around 2023-02-28.
Valuation (modeled)modeled
Provath models Nanospectra Biosciences Inc at approximately $59M (range $6.8M–$173M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.52× the median modeled value of Series A Biotech / Pharma companies in 2022–2024 (21 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 3.3 yr ago; this sector typically re-raises about every 15 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 1.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 77% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 63% of those peers.
Closest niche peers: Laxmi Therapeutic Devices, Inc., Accipiter Biosciences Inc., Ten Bay Bio, Inc., Genomic Life, Inc., NJ BIO, Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.